Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerOlivia Pagani, Prudence A. Francis, Alan S. Coates et al.|New England Journal of Medicine|2014Cited by 751
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Barbara Walley, Weixiu Luo et al.|The Lancet Oncology|2015Cited by 179
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)Dieter Koeberle, G. Bodoky, Jean‐François Dufour et al.|Annals of Oncology|2016Cited by 140
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Weixiu Luo et al.|The Lancet Oncology|2017Cited by 122
Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European CentersMonica Ruggeri, Olivia Pagani, Eleonora Pagan et al.|The Breast|2019Cited by 117